DOP2019000233A - Dropropizina en combinacion con ambroxol en la forma farmaceutica de jarabe y tableta - Google Patents

Dropropizina en combinacion con ambroxol en la forma farmaceutica de jarabe y tableta

Info

Publication number
DOP2019000233A
DOP2019000233A DO2019000233A DO2019000233A DOP2019000233A DO P2019000233 A DOP2019000233 A DO P2019000233A DO 2019000233 A DO2019000233 A DO 2019000233A DO 2019000233 A DO2019000233 A DO 2019000233A DO P2019000233 A DOP2019000233 A DO P2019000233A
Authority
DO
Dominican Republic
Prior art keywords
ambroxol
combination
dropropizin
syrup
tablet
Prior art date
Application number
DO2019000233A
Other languages
English (en)
Inventor
Luis Espino Vasquez Jorge
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of DOP2019000233A publication Critical patent/DOP2019000233A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una combinación farmacéutica de ambroxol o una sal farmacéuticamente aceptable del mismo y dropropizina. Asimismo, se refiere a una composición farmacéutica, preferentemente en una forma de administración oral, que contiene dichos ingredientes activos, junto con uno o más aditivos farmacéuticamente aceptables. La invención también se refiere a los procesos de preparación y los procesos de uso de la combinación farmacéutica o la composición farmacéutica de la presente invención.
DO2019000233A 2017-11-16 2019-09-12 Dropropizina en combinacion con ambroxol en la forma farmaceutica de jarabe y tableta DOP2019000233A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2017014725A MX2017014725A (es) 2017-11-16 2017-11-16 Dropropizina en combinacion con ambroxol en la forma farmaceutica de jarabe y tabletas.
PCT/IB2018/052699 WO2019097309A1 (es) 2017-11-16 2018-04-19 Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas

Publications (1)

Publication Number Publication Date
DOP2019000233A true DOP2019000233A (es) 2019-12-15

Family

ID=66538528

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2019000233A DOP2019000233A (es) 2017-11-16 2019-09-12 Dropropizina en combinacion con ambroxol en la forma farmaceutica de jarabe y tableta

Country Status (9)

Country Link
US (2) US20210128496A1 (es)
CL (1) CL2019002446A1 (es)
CO (1) CO2019013645A2 (es)
CR (1) CR20190401A (es)
DO (1) DOP2019000233A (es)
MX (1) MX2017014725A (es)
NI (1) NI201900084A (es)
PE (1) PE20191820A1 (es)
WO (1) WO2019097309A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1203721B (it) * 1983-12-29 1989-02-23 Dompe Farmaceutici Spa Composti otticamente attivi ad attivita' antitosse e sedativa centrale,procedimento per la preparazione e composizioni che li contengono
DE19933148A1 (de) * 1999-07-20 2001-01-25 Boehringer Ingelheim Int Ambroxolhaltige Lutschtablette
KR101915056B1 (ko) * 2012-04-10 2018-11-07 한미약품 주식회사 암브록솔, 레보드로프로피진 및 완충제를 포함하는 경구용 액상 제제 및 이의 제조방법

Also Published As

Publication number Publication date
US20210128496A1 (en) 2021-05-06
US20240082176A1 (en) 2024-03-14
WO2019097309A1 (es) 2019-05-23
CL2019002446A1 (es) 2019-12-13
MX2017014725A (es) 2019-05-17
NI201900084A (es) 2020-04-02
CO2019013645A2 (es) 2020-01-17
PE20191820A1 (es) 2019-12-27
CR20190401A (es) 2019-11-18

Similar Documents

Publication Publication Date Title
CO2019008364A2 (es) Composiciones farmacéuticas que comprenden meloxicam
CO2019000945A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CO2019000938A2 (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos
CO2019000943A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
CO2019000941A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CO2019000944A2 (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
CL2015002304A1 (es) Formas del metil {4,6-diamino-2- [1- (2-fluorobencil)-1h-pirazolo [3,4-b] piridino-3-il] pirimidino-5-il} metil carbamato
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
CO2017002682A2 (es) Composiciones y métodos para recubrimientos cannabinoides para uso en la entrega de fármacos
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
AR115913A1 (es) Formas de dosificación oral biodisponibles, uso, métodos
DOP2019000233A (es) Dropropizina en combinacion con ambroxol en la forma farmaceutica de jarabe y tableta
TR201721700A2 (tr) Saksagli̇pti̇ni̇n ağizda dağilan formülasyonlari
CO2018013792A2 (es) Regímenes de dosificación de vortioxetina para el rápido inicio del efecto antidepresivo
CL2017003465A1 (es) Uso combinado de bumetanida con ácido valproico o una de sus sales farmacéuticamente aceptables para restablecer la homeostasis de cl- y con ello, permitir la preparación de un fármaco efectivo en el tratamiento de la epilepsia, y especialmente, en el tratamiento de la epilepsia refractaria.
AR115724A1 (es) Composición farmacéutica que contiene un péptido
CO2019008347A2 (es) Composición de liberación rápida de cinitaprida y simeticona y proceso para prepararla
AR099330A1 (es) Uso de paricalcitol en el tratamiento de la anemia inflamatoria
PE20151431A1 (es) Formulaciones de lorazepam de liberacion controlada
EA202092800A1 (ru) Фармацевтическая композиция немедленного высвобождения для противовоспалительных лекарственных средств с фамотидином и карбонатом
CO2020006701A2 (es) Composiciones farmacéuticas orales de lorazepam resistentes al alcohol
UA113237U (uk) Фармацевтична комбінація ацеклофенаку і снодійного або заспокійливого компонента